ZNF703 and hematocrit: WRN loss (p=0.018; HR 1.40), UNC5D loss (p=0.017; HR 1.43), ZNF703 loss (p=0.023; HR 1.47), FGFR1 loss (p=0.002; HR 1.70) or amplification (p=0.083; HR 1.36), PRKDC loss (p=0.045; HR 1.74), a loss of at least 2 genes of NRG1, DUSP26 and UNC5D (p=0.016; HR 1.38; 95% CI 1.06-1.80) and LOH at 8p (p=0.021; HR 1.36; 95% CI 1.05-1.76) predicted worse DFS in HT-treated patients but not in HT-naïve patients, suggesting a correlation with HT resistance.